Thus, this model is effective and capable of modeling and predicting the inhibitory activity of reverse transcriptase
by HEPT derivatives.
Analysis of DNA methylation status of the promoter of human telomerase reverse transcriptase
in gastric carcinogenesis.
nucleoside analogue reverse transcriptase
inhibitors (NRTIs), gp120 inhibitors, protease inhibitors, acetylcholinesterase inhibitors.
"Reverset appears to be an excellent addition to our armamentarium of nucleoside reverse transcriptase
To verify that the control was pure RNA, free of residual control DNA, the [10.sup.-3] dilution of the RICO stock solution was tested both with and without reverse transcriptase
. No increase of fluorescence was seen in the absence of reverse transcriptase
(data not shown).
* The combination of Viread and either Epivir (3TC) or Emtriva (FTC) is now recommended as a 2-nuke backbone for regimens based on either a non-nucleoside reverse transcriptase
inhibitor ("non-nuke") or a protease inhibitor.
inhibitors copy the genetic code of HIV and helps it replicate into additional human cells.
These drugs are other nucleoside reverse transcriptase
inhibitors such as lamivudine, and nonnucleoside reverse transcriptase
inhibitors such as nevirapine, and protease inhibitors such as indinavir and ritonavir.
These are called reverse transcriptase
inhibitors, and there are two subclasses within this group--nucleoside reverse transcriptase
inhibitors (NRTI) and non-nucleoside reverse transcriptase
Until recently the only approved form of therapy for HIV infection was treatment with drugs from the class of nucleoside analogue reverse transcriptase
inhibitors (see Table 1), often referred to as RT inhibitors or nucleoside analogues.
In 1970 the American oncologist Howard Martin Temin (b.1934), in his investigation of cancer cells, located an enzyme he called reverse transcriptase
, which could affect the working of DNA in line with information received from RNA, thus making the DNA more responsive to the needs of the cell.
ViiV Healthcare presented at the 22nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 & 2 studies, assessing the safety and efficacy of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC) compared to a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase
inhibitors (NRTIs), tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in treatment-nave, HIV-1 infected adults with baseline viral loads up to 500,000 copies per millilitre (c/mL).